Online inquiry

IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13504MR)

This product GTTS-WQ13504MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SNCA gene. The antibody can be applied in Parkinson's disease (PD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000345.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6622
UniProt ID P37840
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13504MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10696MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ10645MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-3819253
GTTS-WQ12221MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ4349MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIW-8405
GTTS-WQ11406MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ8362MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ15451MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ11906MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-1202
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW